TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Weight Adjusted Low Molecular Weight Heparin in Recurrent Implantation Failure: a Randomized Open Labeled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women ≥18 years and ≤40 years, candidated to a fresh IVF/ICSI cycle with routine ovulation induction protocol~Exclusion Criteria:~v-vCouples candidated to a frozen IVF/ICSI cycle with routine ovulation induction protocol~* Testicular or frozen sperm (TESE procedure not allowed)~* Presence of hormonal disorders not compensated with specific therapy or history of immunological disease (autoimmune thyroiditis, connectivitis, RA, SLE, etc )~* Presence of antiphospholipides autoantibodies or other severe thrombophilia (AT, PS, PC deficiency or homozygous FV Leiden or FIIG20210A, or double eterozygous FV Leiden and FIIG20210A)~* Presence of abnormal platelets count and congenital or acquired coagulopathy ASA or steroid therapy administration

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- parnaparin sodium (Type: EXPERIMENTAL): Women in LMWH arm are administered with routine ovulation induction protocol and prophylactic dose of parnaparin sodium (LMWH), starting the day before the beginning of stimulation phase of the cycle until the result of the procedure is confirmed in terms of pregnancy yes or no and in case of pregnancy until the delivery or the end of pregnancy. Women in the LMWH arm will be tested for blood cell count twice in the first 10 days of therapy.~Parnaparin will be administered at the dose of 100 IU/kg/day from the day before the beginning of stimulation phase of the cycle until the result of the procedure is confirmed in terms of pregnancy yes or no and in case of pregnancy until delivery or the end of the pregnancy.~Used dosages Parnaparin 0.4 4250 UI Parnaparin 0.6 6400 UI
- no treatment (Type: NO_INTERVENTION): Women in the control arm are administered with routine ovulation induction protocol, without the addition of parnaparin sodium.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven prostate cancer~* Know metastatic disease on previous imaging, or PSA value ⩾ 1 ng/ml;~* Castration resistant disease with confirmed testosterone level =\< 50 ng/ml under prior first-line androgen deprivation therapy (ADT)~* New planned treatment with enzalutamide or abiraterone, darolutamide or apalutamide~* Willingness to undergo ARSI throughout the duration of the study as prescribed by the treating uro-oncologist~* Stated willingness to comply with continuation of ARSI treatment for the duration of the study~* Provision of signed and dated informed consent form~Exclusion Criteria:~* Inability to provide written informed consent~* Known inability to remain still and lie flat for duration of each imaging procedure (about 30 minutes)~* Other concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, or investigational therapy~* A baseline superscan pattern on bone scan~* Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, patients with a prior history of malignancy that has been adequately treated and who have been disease free for more than 3 years are eligible

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (68GA-PSMA-11 PET/CT) (Type: EXPERIMENTAL): Patients receive 68Ga-PSMA-11 IV. After 50-100 minutes, patients undergo PET/CT over 20-50 minutes. Patients undergo 68Ga-PSMA-11 PET/CT at baseline, at 1 week and 3 months after initiation of ARSI, and at time of biochemical progression (within 1 year if applicable).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Double Tract Anastomosis and Gastric Tube Anastomosis to Proximal Gastrectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Preoperative endoscopy and biopsy confirmed upper third gastric adenocarcinoma, and predictively feasible of proximal gastrectomy ;~2. Predictively resectable diseases, early gastric cancer, of preoperative staging JGCA 14th Edition cT1N0M0-T2N0M0;~3. Age：≤75 years, or ≥18 years;~4. Without serious disease and malignance disease;~5. Patients without previous history of upper abdominal surgery;~6. WHO performance score ≤2, ASA score ≤3;~7. No limit to sexual and race;~8. informed consent required.~Exclusion Criteria:~1. With the history of the malignance disease;~2. Patients with other severe complications cannot tolerate surgery: such as severe heart and lung diseases, heart function below clinical stage 2, uncontrollable hypertension, pulmonary infection, moderate to severe COPD, chronic bronchitis, severe diabetes and / or renal insufficiency, severe hepatitis and / or function below the rank of CHILD B grade, and severe malnutrition, etc.~3. Patients treated with neoadjuvant chemotherapy or radiation therapy which might affect the efficacy observation;~4. Severity mental diseases;~5. After signature the Clinical trial agreement, patients and their agent will quit the trial;~6. primary lesion cannot be resected in the pattern of transabdominal proximal gastrectomy, but for total gastrectomy, Whipple's procedure, or combined organ resection or with a transthoracic approach surgery~7. After signature the Clinical trial agreement, patients and their agent will quit the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group B (double-track anastomosis) (Type: EXPERIMENTAL): Patients in the Group B will received the double-track anastomosis with proximal gastrectomy.
- Group A (Gastric tube anastomosis) (Type: OTHER): Patients in the Group A (Gastric tube anastomosis) will take the gastric tube anastomosis with proximal gastrectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Thetaburst Stimulation for the Treatment of Refractory Epilepsy - Safety, Feasibility and Proof-of-concept

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Refractory unifocal neocortical epilepsy with a well-defined ictal onset zone based on a standardized presurgical evaluation~* ≥ 4 seizures/month, for at least six months~* On a stable drug regimen for at least 2 months~* IQ \>70~* Reliable completion of a seizure diary by patient or caretakers~* Therapeutic compliance in the past~* Informed consent signed~Exclusion Criteria:~* Pregnancy, short-term birth wish or childbearing age without adequate birth control~* History of psychogenic non-epileptic seizures~* Intracranial metal hardware (excluding dental filling): surgical clips, shrapnell, electrodes under the stimulation area~* Presence of pacemaker, implantable cardioverter-defibrillator (ICD), permanent medication pumps, cochlear implants or deep brain stimulation (DBS)~Patients with a vagus nerve stimulator are not excluded, provided that adequate distance between the coil and the implanted material can be maintained.~As the short duration of the study will not interfere with an ongoing presurgical evaluation and/or its eventual conclusion, the patients in the course of the evaluation or awaiting surgery are also eligible for inclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- continuous thetaburst stimulation (Type: EXPERIMENTAL): Transcranial magnetic stimulation over the epileptogenic focus using a cTBS stimulation protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Alpha-Lipoic Acid in Diabetic Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adult age ≥ 18 years~* patient with diagnosed type 2 diabetes (history of pathological hyperglycemia according to WHO and HbA1c standards \>7% or ongoing treatment with oral antidiabetic agents).~* Patients with stable cardiomyopathy (no hospitalization in cardiology in the month before inclusion) with a left ventricular ejection fraction (LVEF) \<50%.~* patient who has signed an informed consent form~* For women of childbearing age: effective contraception followed for at least 3 months before the start of the study and agreeing to keep it for the duration of the study.~* affiliation to a social security scheme.~Exclusion Criteria:~subjects:~* With a coronary event in the year before inclusion.~* With symptoms of cardiac ischemia at inclusion.~* Pregnant or breastfeeding woman~* Severe renal insufficiency~* Using antioxidant molecules in the 6 months prior to inclusion.~* Using drugs that can activate PPARs (Fibrates, Telmisartan, Enalaprilat).~* Using anti-inflammatory drugs.~* Suffering from acute infectious diseases and inflammatory diseases.~* Hypersensitivity or a history of hypersensitivity reaction to gadoteric acid, meglumine or any drug containing gadolinium.~Non-inclusion criteria related to MRI:~* with an implanted vascular stent less than 6 weeks before the examination;~* carrier of an implanted biomedical device deemed not safe or unsafe in the list: http://www.mrisafety.com/TheList_search.asp;~* Beneficiary of an acquisition procedure that does not respect the conditions required by conditional use in a subject carrying an implanted biomedical material considered conditional in the list: http://www.mrisafety.com/TheList_search.asp;~* carrier of a ferromagnetic intraocular or intracranial foreign body close to the nerve structures;~* carrying biomedical equipment such as a cardiac, neural or sensory pacemaker (cochlear implant) or a ventricular bypass valve without medical and paramedical supervision trained to perform MRI in these subjects;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alpha-Lipoic Acid group (Type: ACTIVE_COMPARATOR): None
- placebo group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: This Trial is a Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Previously untreated patients with DLBCL of the breast.~* Patients must have CD20 positive tumors.~* Stage IE or IIE.~* Must have at least one objective measurable or evaluable disease. Baseline measurements and evaluations must be obtained within 4 weeks of registration to the study.~* Patients must have an ECOG performance status 0-2.~* Patients must have adequate organ function as evidenced by the following laboratory studies ( within 2 weeks prior to registration):~  * Creatinine Clearance \> 50 ml/min~ * Total bilirubin \< 2.0 mg/dl and AST \< 2 x upper limit of normal. If documented hepatic involvement with lymphoma, total bilirubin can be \< 3 x ULN, and AST \< 5 x ULN.~ * Absolute neutrophil count \> 1500/mm3 and platelet count \> 100,000/mm3. If documented bone marrow involvement with lymphoma, absolute neutrophil count \> 500/mm3 and platelet count \> 50,000/mm3.~* Patients must be age \> 18 years.~* Patients must have a normal left ventricular ejection fraction to be eligible.~Exclusion Criteria:~* historical or radiographic evidence of CNS metastasis including previously treated, resected or asymptomatic brain lesions or leptomeningeal involvement.~* pregnant or breast feeding patients. Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of contraception.~* active infection requiring parental antibiotics.~* known HIV infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Heart Rate on Cardiac Index in Patients With Left Ventricular Hypertrophy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled heart surgery including thoracotomy~* Ejection fraction \> 45%~* Duration of QRS complex \< 120 milliseconds~* Sinus rhythm~* Planned perioperative temporary pacemaker~Group: Left ventricular hypertrophy:~Thickness of interventricular septum and posterior wall \>11 mm.~Group: No left ventricular hypertrophy:~Thickness of interventricular septum and posterior wall \<11 mm.~Exclusion Criteria:~* Active endocarditis~* Severe mitral insufficiency~* No patient consent

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Normal left ventricular size (Type: PLACEBO_COMPARATOR): Postoperative patient with normal left ventricular size
- Left ventricular hypertrophy (Type: ACTIVE_COMPARATOR): Postoperative patient with left ventricular hypertrophy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate THB001 in Adult Patients With Chronic Cold Urticaria

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Women and Men ages 18-75~2. Diagnosed with chronic, cold inducible urticaria for at least 3 months prior to starting the study and refractory to antihistamine treatment~3. Positive cold stimulation test assessed by TempTest® at the Screening and Baseline visits~4. Considered healthy as assessed by medical evaluation including review of medical history, physical examination, vital signs, laboratory tests and ECG recording~5. Willing and able to participate in all visits, undergo all study procedures and adhere to study restrictions~Key Exclusion Criteria:~1. A diagnosis of acute urticaria or non-cold chronic inducible urticaria~2. Ongoing treatment with immunosuppressant drugs (corticosteroids, cyclosporine, azathioprine, methotrexate, omalizumab, dupilumab, sulfasala-zine, dapsone or others)~3. A positive test for pregnancy, HIV, Hepatitis B or Hepatitis C~4. Clinical laboratory values outside of the normal ranges at the Screening visit~5. History of any clinically significant abnormality that would contraindicate participation~There are additional criteria that your study doctor will review with you to confirm you are eligible for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- THB001 Dose Level A (Type: EXPERIMENTAL): None
- THB001 Dose Level B (Type: EXPERIMENTAL): None
- THB001 Dose Level C (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Social Support Intervention Targeting Patients Treated for Cardiac Disease Who Experience Loneliness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients treated for Ischemic heart disease (CABG or PCI), valve disease (TAVR, SAVR), and arrhythmia (ICD, pacemaker implantation or ablation) treated at Rigshospitalet and classified as high risk lonely according to the High Risk Loneliness (HiRL) tool~Exclusion Criteria:~* Patients who are unable to provide written consent, therefore, patients with severe cognitive or physical dysfunction will not be approached

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): Six month social support intervention following in hospital cardiac treatment
- Control (Type: NO_INTERVENTION): Regular follow-up

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient under psychiatric treatment order for violent crime~* More than two violent incidents in the year preceding inclusion, of which at least one within the last three months~* Patient is undergoing psychiatric treatment~* Informed consent~Exclusion Criteria:~* Unable for informed consent~* Intolerance for any prescription compound~* Severe liver failure (Child-Pugh grade c) of renal failure (creatinine clearance \< 15 ml/min.)~* Increased risk of coronary vasospasm: symptoms of vascular disorder (including angina pectoris), history of vascular incidents, severe HBP, ECG-abnormalities in history or at screening prior to inclusion, vascular of cardial souffles.~* History of vascular incidents, hyperlipidaemia, severe HBP, DM~* Use of vasoconstrictive agents such as ergotamine derivates including methysergide, or other triptans.~* Increased risk of serotonergic syndrome: use of irreversible MAO-blocker~* Age \< 18 yr. or \> 65 yr.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): four week double blind placebo treatment phase
- naratriptan (Type: ACTIVE_COMPARATOR): four week double blind experimental treatment using daily naratriptan tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
1. Patient criteria : Donor Treg infusion (DTI) and control arms.~* Signed informed consent.~* Grafts from HLA-identical siblings or HLA-matched unrelated donor (1 of 10 HLA-mismatch is allowed).~* ≥ 18 years of age.~* Steroid-refractory or steroid-resistant chronic GVHD defined as:~  * development of 1 or more new sites of disease while being treated for chronic GVHD,~ * progression of existing sites of disease while receiving treatment for chronic GVHD,~ * failure to improve despite at least 1 month of standard treatment for chronic GVHD.~or severe chronic GVHD and contra-indication to the use of steroids and at least failed one prior line of treatment.~* Severe chronic GVHD according to NIH definition.~* No prior failure of rapamycine as treatment for chronic GVHD~* No contra-indication to the use of rapamycin.~* No alemtuzumab administration in the last 6 months.~* GFR \> 25 mL/min.~* No HIV seropositivity.~* No fungal infection with radiological progression after treatment with amphotericine B or active azoles for \> 1 month.~* No other uncontrolled infection.~* No progression of the hematological malignancy.~* Karnofsky performance score ≥ 70%.~* DLCO \> 35% and no need of supplemental continuous oxygen.~* No active post-transplant microangiopathy and no previous microangiopathy while on rapamycine.~* No uncontrolled hypertriglyceridemia.~  2 Donor criteria : DTI arm only.~* Donor ≥ 18 years of age.~* Written informed consent to perform apheresis from the donor (all patients) and permission from the third party donor registry (in case of unrelated donor).~* Standard criteria for leukapheresis and DLI following complete work-up according to standard procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Donor Treg infusion arm (Type: EXPERIMENTAL): Condition:Patients treated with steroids for a chronic GVHD occurring after allogeneic cell transplantation. Patients who have refractory chronic GVHD will be eligible. Patients in this arm will be first treated with Rapamycin while CNI (if any) will be discontinued and infused whith Treg cells 60-90 days after.
- Control (Type: ACTIVE_COMPARATOR): Condition:Patients treated with steroids for a chronic GVHD occurring after allogeneic cell transplantation. Patients who have refractory chronic GVHD will be eligible. Patients in this arm will be treated with Rapamycin which is an alternative immunosupression strategy allowing to fight againt GVHD and CNI (if any) will be discontinued.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues